Intratumoral delivery of inactivated modified vaccinia virus Ankara (iMVA) induces systemic antitumor immunity via STING and Batf3-dependent dendritic cells

Peihong Dai(Memorial Sloan Kettering Cancer Center), Weiyi Wang(Memorial Sloan Kettering Cancer Center), Ning Yang(Memorial Sloan Kettering Cancer Center), Cristian Serna‐Tamayo(Memorial Sloan Kettering Cancer Center), Jacob Ricca(Memorial Sloan Kettering Cancer Center), Dmitriy Zamarin(Memorial Sloan Kettering Cancer Center), Stewart Shuman(Memorial Sloan Kettering Cancer Center), Taha Merghoub(Memorial Sloan Kettering Cancer Center), Jedd D. Wolchok(Memorial Sloan Kettering Cancer Center), Liang Deng(Memorial Sloan Kettering Cancer Center)
Science Immunology
May 5, 2017
10.1126/sciimmunol.aal1713
Cited by 123Open Access
Full Text

Abstract

DCs are essential for iMVA immunotherapy. The combination of intratumoral delivery of iMVA and systemic delivery of immune checkpoint blockade generated synergistic antitumor effects in bilateral tumor implantation models as well as in a unilateral large established tumor model. Our results suggest that inactivated vaccinia virus could be used as an immunotherapeutic agent for human cancers.

Related Papers

No related papers found

Powered by citation graph analysis